


BIOSIMILARS OPPORTUNITY IN OREGON

Oregon could save as much as **\$208.09 million annually** by increasing use of biosimilars, according to an October 2019 study by Pacific Research Institute.¹

Biosimilars provide a lower-cost alternative to treat some of the most aggressive diseases, including cancer, arthritis, and autoimmune diseases, often at a lower cost compared to reference biologics.

Any serious policy proposal to lower healthcare costs must include biosimilars to unlock billions in savings.

BIOSIMILARS CAN SAVE OREGON MONEY



25%
MARKET
SHARE
\$71.51
MILLION

50%
MARKET
SHARE
\$140.04
MILLION

75%
MARKET
SHARE
\$208.09
MILLION

NATIONWIDE SAVINGS FROM THE NEXT GENERATION OF LOWER-COST DRUGS

Biosimilar use currently
saves the healthcare system
\$240.4 MILLION
ANNUALLY.

19.8%
(OR \$47.5 MILLION)
of the savings is being realized
by state Medicaid programs.

56.9%
(OR \$136.8 MILLION)
is being realized by the
commercial market.

The US could save as much as \$2.5 billion to \$7.2 billion annually in system-wide healthcare savings, if biosimilars' market share increased to 25% or up to 75% of the market, respectively.

Biosimilars are a lower-cost alternative to expensive biologics, with a savings of 30% on average compared to the reference product, but misaligned incentives have made these medicines difficult for patients to access and physicians to prescribe.

Without action, patients and taxpayers in Oregon and across the country will be forced to pay higher prices unless Congress or the President enacts simple policy changes to unlock these savings.

1. Winegarden, W. The Biosimilar Opportunity: A State Breakdown. October 2019. Pacific Research Institute Center for Medical Economics and Innovation. https://www.pacificresearch.org/wp-content/uploads/2019/10/BiosimilarSavings_web.pdf. Accessed December 9, 2019.